Helix Acquisition(HLXB) - 2025 Q4 - Annual Results

Exhibit 99.1 BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress SOUTH SAN FRANCISCO, Calif., March 5, 2026 — BridgeBio Oncology Therapeutics, Inc. ("BBOT") (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update, including highlights of pipeline progress. BBOT's portfolio of clinical-stage RAS-path ...